{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Rate of Complete Donor Chimerism - Blood\n\nSummarized using standard descriptive statistics.","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.\n\nNote: \\*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients, who were able to complete testing","reportingStatus":"POSTED","timeFrame":"Day 30","title":"Rate of Complete Donor Chimerism - Blood","type":"SECONDARY","unitOfMeasure":"percentage of participants"}